BPMX - BPMX Stock Soars 30% on Positive Trial Results for BPX-04

Small biotech company BioPharmX Corp (NYSE:BPMX) has been on a tear in Tuesday’s trading session, and BPMX stock rose by as much as 30% on the back of highly positive news about its topical minocycline gel BPX-04.

According to the announcement made today, BioPharmX received highly positive results from the Phase 2b trial of its product, BPX-04. BPX-04 is meant for the treatment of papulopustular rosacea, which is a form of skin disorder. The important fact about the results from the trial is that the product met both the endpoints that were necessary ...